Circulating tryptophan metabolites and risk of colon cancer: Results from case-control and prospective cohort studies
Autor: | David Achaintre, Pekka Keski-Rahkonen, Matty P. Weijenberg, Verena Katzke, Nikos Papadimitriou, Ellen Kampman, Augustin Scalbert, Audrey Gicquiau, Sandra Colorado-Yohar, Neil Murphy, Per Magne Ueland, Ruth C. Travis, Jennifer Ose, Anne J.M.R. Geijsen, Elisabete Weiderpass, María José Sánchez, Andrea Gsur, Andreas Baierl, Marc J. Gunter, Cornelia M. Ulrich, Biljana Gigic, Eva Ardanaz, Vittorio Krogh, Bas Bueno-de-Mesquita, Stefanie Brezina, Eline H. van Roekel, Tanja Gumpenberger, Nina Habermann, Rudolf Kaaks, Matthias B. Schulze |
---|---|
Přispěvatelé: | RS: GROW - R1 - Prevention, Epidemiologie |
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Male
Cancer Research Nutrition and Disease Colorectal cancer Gastroenterology DISEASE COLORECTAL-CANCER IDO chemistry.chemical_compound MARKERS Risk Factors ADIPONECTIN Voeding en Ziekte Epidemiology Prospective Studies Prospective cohort study Aged 80 and over Middle Aged INSULIN European Prospective Investigation into Cancer and Nutrition serotonin Oncology colon cancer Colonic Neoplasms Female Adult medicine.medical_specialty Article INFLAMMATION Internal medicine medicine Humans tryptophan plasma Aged VLAG business.industry Cancer PLASMA SEROTONIN Odds ratio medicine.disease kynurenine Logistic Models WHOLE-GRAIN INTAKE chemistry Case-Control Studies Serotonin business Kynurenine |
Zdroj: | International Journal of Cancer, 149(9), 1659-1669 Int J Cancer International Journal of Cancer 149 (2021) 9 International Journal of Cancer, 149(9), 1659-1669. Wiley |
ISSN: | 1097-0215 0020-7136 |
Popis: | Dysregulation of tryptophan metabolism has been linked to colorectal tumorigenesis, however, epidemiological studies investigating tryptophan metabolites in relation to colorectal cancer risk are limited. We studied associations of plasma tryptophan, serotonin, and kynurenine with colon cancer risk in two studies with cancer patients and controls, and in one prospective cohort: ColoCare Study (110 patients/153 controls), the Colorectal Cancer Study of Austria (CORSA; 46 patients/390 controls), and the European Prospective Investigation into Cancer and Nutrition (EPIC; 456 matched case-control pairs). Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for colon cancer risk. Tryptophan was inversely associated with colon cancer risk in ColoCare [OR per 1-standard deviation (SD) = 0.44; 95% CI, 0.31-0.64] and EPIC (OR per 1-SD = 0.86; 95% CI, 0.74-0.99). Comparing detectable versus non-detectable levels, serotonin was positively associated with colon cancer in CORSA (OR = 6.39; 95% CI, 3.61-11.3) and EPIC (OR = 2.03; 95% CI, 1.20-3.40). Kynurenine was inversely associated with colon cancer in ColoCare (OR per 1-SD = 0.74; 95% CI, 0.55-0.98), positively associated in CORSA (OR per 1-SD = 1.79; 95% CI, 1.27-2.52), while no association was observed in EPIC. The kynurenine-to-tryptophan ratio was positively associated with colon cancer in ColoCare (OR per 1-SD = 1.38; 95% CI, 1.03-1.84) and CORSA (OR per 1-SD = 1.44; 95% CI, 1.06-1.96), but not in EPIC. These results suggest that higher plasma tryptophan may be associated with lower colon cancer risk, while increased serotonin may be associated with a higher risk of colon cancer. The kynurenine-to-tryptophan ratio may also reflect altered tryptophan catabolism during colon cancer development. This article is protected by copyright. All rights reserved. |
Databáze: | OpenAIRE |
Externí odkaz: |